{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:58:03Z","timestamp":1782863883357,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-026-04216-z","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:27:15Z","timestamp":1777181235000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction"],"prefix":"10.1007","volume":"124","author":[{"given":"Shun","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironao","family":"Nukariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Sugawasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihoko","family":"Komine-Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-3804","authenticated-orcid":false,"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"4216_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"4216_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496\u2013507 (John Wiley & Sons, Ltd;).","journal-title":"Br J Haematol"},{"key":"4216_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609 (United States).","journal-title":"N Engl J Med"},{"key":"4216_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, H\u00e4nel M, Raab MS, Mann C, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42:26\u201337 (United States).","journal-title":"J Clin Oncol"},{"key":"4216_CR5","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report. Blood. 2015;125:2068\u201374.","journal-title":"Blood"},{"issue":"29","key":"4216_CR6","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'agostino","year":"2022","unstructured":"D\u2019agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J of Clin Oncol. 2022;40(29):3406\u201318.","journal-title":"J of Clin Oncol"},{"key":"4216_CR7","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1007\/s00277-021-04634-5","volume":"100","author":"K Sato","year":"2021","unstructured":"Sato K, Okazuka K, Ishida T, Sakamoto J, Kaneko S, Nashimoto J, et al. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Ann Hematol. 2021;100:2989\u201395 (Springer Berlin Heidelberg;).","journal-title":"Ann Hematol"},{"key":"4216_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761\u20137.","journal-title":"Haematologica"},{"issue":"2","key":"4216_CR9","doi-asserted-by":"publisher","first-page":"2281657","DOI":"10.1080\/07853890.2023.2281657","volume":"55","author":"J Wang","year":"2023","unstructured":"Wang J, Shen N, Shen X, Zhang R, Jin Y, Li J, et al. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease. Annals of Med. 2023;55(2):2281657.","journal-title":"Annals of Med"},{"key":"4216_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-025-01821-w","volume":"25","author":"J Zhao","year":"2025","unstructured":"Zhao J, Cui Y, Fang B. Therapeutic options for extramedullary involvement in multiple myeloma. Clin Exp Med. 2025;25:1\u201318 (Springer International Publishing).","journal-title":"Clin Exp Med"},{"key":"4216_CR11","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235\u201341.","journal-title":"Nat Med"},{"issue":"4","key":"4216_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","volume":"101","author":"RW Tsang","year":"2018","unstructured":"Tsang RW, Campbell BA, Goda JS, Kelsey CR, Kirova YM, Parikh RR, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology groupinternational lymphoma radiation oncology group. Intern J of Radiat Oncol Biol Phys. 2018;101(4):794\u2013808.","journal-title":"Intern J of Radiat Oncol Biol Phys"},{"issue":"10","key":"4216_CR13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/COC.0000000000000734","volume":"43","author":"J Curry","year":"2020","unstructured":"Curry J, O\u2019steen L, Morris CG, Kirwan JM, Mendenhall WM. Long-term Outcomes After Definitive Radiation Therapy for Solitary Plasmacytoma. American J of Clin Oncol. 2020;43(10):709\u201313.","journal-title":"American J of Clin Oncol"},{"key":"4216_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-0044-1787535","volume":"19","author":"LB Palavani","year":"2024","unstructured":"Palavani LB, Bapat A, Batista S, Mendes JP, Oliveira LB, Bertani R. Extramedullary intracranial plasmacytomas: A systematic review of literature. Asian J Neurosurg. 2024;19:137\u201344.","journal-title":"Asian J Neurosurg"},{"key":"4216_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-025-01378-4","volume":"23","author":"Z Chen","year":"2026","unstructured":"Chen Z, Zhu Z, Hu T, Yao C, Wu T. Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy. Cell Mol Immunol. 2026;23:1\u201314 (Springer US;).","journal-title":"Cell Mol Immunol"},{"key":"4216_CR16","volume":"29","author":"A Visram","year":"2021","unstructured":"Visram A, Kourelis TV. Aging-associated immune system changes in multiple myeloma: the dark side of the moon. Cancer Treat Res Commun. 2021;29:100494 (Elsevier Ltd;).","journal-title":"Cancer Treat Res Commun"},{"key":"4216_CR17","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","volume":"116","author":"G G\u00f6rg\u00fcn","year":"2010","unstructured":"G\u00f6rg\u00fcn G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116:3227\u201337.","journal-title":"Blood"},{"key":"4216_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9:1\u201312 (Journal of Hematology & Oncology;).","journal-title":"J Hematol Oncol"},{"key":"4216_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1186\/s12885-024-13309-z","volume":"24","author":"D Liang","year":"2024","unstructured":"Liang D, Yan Y, Bai S, Xu W, Wang Q, Feng D, et al. The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study. BMC Cancer. 2024;24:1551.","journal-title":"BMC Cancer"},{"key":"4216_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346 (England;).","journal-title":"Lancet Oncol"},{"issue":"4","key":"4216_CR21","first-page":"1297","volume":"109","author":"L Notarfranchi","year":"2023","unstructured":"Notarfranchi L, Accardi F, Mancini C, Martella E, Bonomini S, Segreto R, et al. CD38 expression by plasma cells in extramedullary multiple myeloma. Haematologica. 2023;109(4):1297\u2013300.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04216-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04216-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04216-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:12:00Z","timestamp":1782861120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04216-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4216"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04216-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.H. received honoraria from Sanofi, Gilead Sciences, and Bristol-Myers Squibb. H.T. has received honoraria from Sanofi, Janssen, Gilead Sciences, Chugai, Kyowa Kirin, Nippon Shinyaku, Takeda, and Bristol-Myers Squibb. H.N. has received research grants from MSD, Asahi Kasei Pharma, Astellas, AbbVie, Japan Blood Products Organization, Eisai, Otsuka Pharmaceutical, Ono Pharma, Kyowa Kirin, Sanofi, Shionogi, Daiichi Sankyo, Taiho, Takeda, Mitsubishi Tanabe, Chugai, Teijin Pharma, Eli Lilly, Nippon Kayaku, Nihon Pharmaceutical, Boehringer Ingelheim, Nippon Shinyaku, Taisho Pharmaceutical, and Pfizer. K.M. has received honoraria from Sanofi, Janssen, AstraZeneca, Chugai, Kyowa Kirin, Takeda, Bristol-Myers Squibb, Nippon Shinyaku, SymBio, and Ono Pharmaceuticals. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted as part of an observational study on multiple myeloma and was approved by the Institutional Review Board of Nihon University Itabashi Hospital (approval No. RK-240514\u20136). The study was conducted in accordance with the most recent version of the Declaration of Helsinki (updated 2008).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient. Additionally, the patient provided specific written consent for the use of anonymized residual blood samples and exploratory immunophenotyping analyses.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient has consented to the submission and publication of this case report and any anonymized laboratory and\/or imaging data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}